Skip to main content
Erschienen in: International Urogynecology Journal 7/2007

01.07.2007 | Original Article

Prophylactic single-dose prulifloxacin for catheter-associated urinary tract infection after tension-free vaginal tape procedure

verfasst von: Fabio Ghezzi, Maurizio Serati, Antonella Cromi, Stefano Uccella, Stefano Salvatore, Pierfrancesco Bolis

Erschienen in: International Urogynecology Journal | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

The purpose of the study was to evaluate whether antibiotic prophylaxis with a single dose of prulifloxacin after tension-free vaginal tape (TVT) procedure decreases catheter-associated urinary tract infections (UTIs). Patients undergoing TVT procedure receiving a single dose of prulifloxacin (600 mg) 10 h before catheter removal (n = 54) were compared with historical controls who have had no treatment (n = 60). All patients had an indwelling urethral catheter in situ for 24 h. Urine specimens for culture were collected preoperatively, before Foley removal, and 7 days postoperatively in both groups. Main outcome measures were significant bacteriuria and symptomatic UTI at catheter removal and 1 week postoperatively. No patient had a positive urine culture in the prulifloxacin group compared with 14 (23.3%) in the control group at catheter removal (P = 0.0001). Ten out of 14 (71.4%) women with a positive catheter urine culture had a symptomatic UTI. One week after surgery no difference was found in the rate of significant bacteriuria between groups. Our data suggest that a prophylactic single dose of prulifloxacin could help to reduce the rate of symptomatic and asymptomatic UTIs after short-term urethral catheterization in women undergoing TVT procedure.
Literatur
1.
Zurück zum Zitat Car J (2006) Urinary tract infections in women: diagnosis and management in primary care. BMJ 332:94–97PubMedCrossRef Car J (2006) Urinary tract infections in women: diagnosis and management in primary care. BMJ 332:94–97PubMedCrossRef
2.
Zurück zum Zitat Haley RW, Culver DH, White JW, Morgan WM, Emori TG (1985) The nationwide nosocomial infection rate: a need for vital statistics. Am J Epidemiol 121:159–167PubMed Haley RW, Culver DH, White JW, Morgan WM, Emori TG (1985) The nationwide nosocomial infection rate: a need for vital statistics. Am J Epidemiol 121:159–167PubMed
3.
Zurück zum Zitat Kunin CM (1984) Genitourinary infections in the patient at risk: extrinsic risk factors. Am J Med 73:130–139 Kunin CM (1984) Genitourinary infections in the patient at risk: extrinsic risk factors. Am J Med 73:130–139
4.
Zurück zum Zitat Platt R, Polk BF, Murdock B, Rosner B (1982) Mortality associated with nosocomial urinary-tract infection. New Engl J Med 307:637–642PubMedCrossRef Platt R, Polk BF, Murdock B, Rosner B (1982) Mortality associated with nosocomial urinary-tract infection. New Engl J Med 307:637–642PubMedCrossRef
5.
Zurück zum Zitat Niël-Weise BS, van den Brock PJ (2005) Antibiotic policies for short-term bladder drainage in adults. The Cochrane database of systematic reviews, issue 3 Niël-Weise BS, van den Brock PJ (2005) Antibiotic policies for short-term bladder drainage in adults. The Cochrane database of systematic reviews, issue 3
6.
Zurück zum Zitat Mountokalakis T, Skounakis M, Tselentis J (1985) Short-term versus prolonged systemic antibiotic prophylaxis in patients treated with indwelling catheters. J Urol 134:506–508PubMed Mountokalakis T, Skounakis M, Tselentis J (1985) Short-term versus prolonged systemic antibiotic prophylaxis in patients treated with indwelling catheters. J Urol 134:506–508PubMed
7.
Zurück zum Zitat Jaffe R, Altaras M, Fejgin M, Ben-Aderet N (1985) Prophylactic single-dose co-trimoxazole for prevention of urinary tract infection after abdominal hysterectomy. Chemotherapy 31:476–479PubMedCrossRef Jaffe R, Altaras M, Fejgin M, Ben-Aderet N (1985) Prophylactic single-dose co-trimoxazole for prevention of urinary tract infection after abdominal hysterectomy. Chemotherapy 31:476–479PubMedCrossRef
8.
Zurück zum Zitat van der Wall E, Verkooyen RP, Mintjes-de Groot J, OOstinga J, van Dijk A, Hustinx WNM, Verbrugh HA (1992) Prophylactic ciprofloxacin for catheter-associated urinary-tract infection. Lancet 339:946–951PubMedCrossRef van der Wall E, Verkooyen RP, Mintjes-de Groot J, OOstinga J, van Dijk A, Hustinx WNM, Verbrugh HA (1992) Prophylactic ciprofloxacin for catheter-associated urinary-tract infection. Lancet 339:946–951PubMedCrossRef
9.
Zurück zum Zitat Wazait HD, Patel HR, van der Muelen JHP, Ghei M, Al-Buheissi S, Kelsey M, Miller RA, Emberton M (2004) A pilot randomized double-blind placebo-controlled trial on the use of antibiotics on urinary catheter removal to reduce the rate of urinary tract infection: the pitfalls of ciprofloxacin. BJU Int 94:1048–1050PubMedCrossRef Wazait HD, Patel HR, van der Muelen JHP, Ghei M, Al-Buheissi S, Kelsey M, Miller RA, Emberton M (2004) A pilot randomized double-blind placebo-controlled trial on the use of antibiotics on urinary catheter removal to reduce the rate of urinary tract infection: the pitfalls of ciprofloxacin. BJU Int 94:1048–1050PubMedCrossRef
10.
Zurück zum Zitat Yoshida Y, Mitsuashi S (1993) Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone. Antimicrob Agents Chemother 37:793–800PubMed Yoshida Y, Mitsuashi S (1993) Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone. Antimicrob Agents Chemother 37:793–800PubMed
11.
Zurück zum Zitat Prats G, Roig C, Miro E, Navarro F, Mirelis B (2002) In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones. Eur J Clin Microbiol Infect Dis 21:328–334PubMedCrossRef Prats G, Roig C, Miro E, Navarro F, Mirelis B (2002) In vitro activity of the active metabolite of prulifloxacin (AF 3013) compared with six other fluoroquinolones. Eur J Clin Microbiol Infect Dis 21:328–334PubMedCrossRef
12.
13.
Zurück zum Zitat Matera MG (2006) Pharmacologic characteristics of prulifloxacin. Pulm Pharmacol Ther 19:20–29PubMedCrossRef Matera MG (2006) Pharmacologic characteristics of prulifloxacin. Pulm Pharmacol Ther 19:20–29PubMedCrossRef
14.
Zurück zum Zitat Prats G, Rossi V, Salvatori E, Mirelis B (2006) Prulifloxacin: a new antibacterial fluoroquinolone. Export Rev Anti Infect Ther 4:27–41CrossRef Prats G, Rossi V, Salvatori E, Mirelis B (2006) Prulifloxacin: a new antibacterial fluoroquinolone. Export Rev Anti Infect Ther 4:27–41CrossRef
15.
Zurück zum Zitat Carmignani G, De Rose AF, Olivieri L, Salvatori E, Rosignoli MT, Dionisio P (2005) Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. Urol Int 74:326–331PubMedCrossRef Carmignani G, De Rose AF, Olivieri L, Salvatori E, Rosignoli MT, Dionisio P (2005) Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. Urol Int 74:326–331PubMedCrossRef
16.
Zurück zum Zitat Cervigni M, Orticelli G, Bologna M, Natale F, Salvatori E, Di Loreto G, Dionisio P (2003) Single-dose prulifloxacin versus single-dose pefloxacin in the treatment of acute uncomplicated urinary tract infection in women. Urogynaecol Int J 17:69–77 Cervigni M, Orticelli G, Bologna M, Natale F, Salvatori E, Di Loreto G, Dionisio P (2003) Single-dose prulifloxacin versus single-dose pefloxacin in the treatment of acute uncomplicated urinary tract infection in women. Urogynaecol Int J 17:69–77
17.
Zurück zum Zitat Ghezzi F, Serati M, Cromi A, Uccella S, Salvatore S, Triacca P, Bolis PF (2005) Tension-free vaginal tape for the treatment of urodynamic stress incontinence with intrinsic sphinteric deficiency. Int Urogynecol J Pelvic Floor Dysfunct 7:1–5 Ghezzi F, Serati M, Cromi A, Uccella S, Salvatore S, Triacca P, Bolis PF (2005) Tension-free vaginal tape for the treatment of urodynamic stress incontinence with intrinsic sphinteric deficiency. Int Urogynecol J Pelvic Floor Dysfunct 7:1–5
18.
Zurück zum Zitat Ghezzi F, Cromi A, Raio L, Bergamini V, Triacca P, Serati M, Kuhn A (2005) Influence of anesthesia and hydrodissection on the complication rate after tension-free vaginal tape procedure. Eur J Obstet Gynecol Reprod Biol 118:96–100PubMedCrossRef Ghezzi F, Cromi A, Raio L, Bergamini V, Triacca P, Serati M, Kuhn A (2005) Influence of anesthesia and hydrodissection on the complication rate after tension-free vaginal tape procedure. Eur J Obstet Gynecol Reprod Biol 118:96–100PubMedCrossRef
19.
Zurück zum Zitat Abrams P, Cardozo L, Fall M et al (2003) The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology 61:37–49PubMedCrossRef Abrams P, Cardozo L, Fall M et al (2003) The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology 61:37–49PubMedCrossRef
20.
Zurück zum Zitat Nygaard IE, Kreder KJ (1994) Complications of incontinence surgery. Int Urogynecol J 5:353–360CrossRef Nygaard IE, Kreder KJ (1994) Complications of incontinence surgery. Int Urogynecol J 5:353–360CrossRef
21.
Zurück zum Zitat Rogers RB, Kammerer-Doak D, Olsen A, Thompson PK, Walters MD, Lukacz ES, Qualls C (2004) A randomized, double-blind, placebo-controlled comparison of the effect of nitrofurantoin monohydrate macrocrystals on the development of urinary tract infections after surgery for pelvic organ prolapse and/or stress urinary incontinence with suprapubic catheterization. Am J Obstet Gynecol 191:182–187PubMedCrossRef Rogers RB, Kammerer-Doak D, Olsen A, Thompson PK, Walters MD, Lukacz ES, Qualls C (2004) A randomized, double-blind, placebo-controlled comparison of the effect of nitrofurantoin monohydrate macrocrystals on the development of urinary tract infections after surgery for pelvic organ prolapse and/or stress urinary incontinence with suprapubic catheterization. Am J Obstet Gynecol 191:182–187PubMedCrossRef
22.
Zurück zum Zitat Zagni R, Orticelli G, Rosignoli MT, Dionisio P (1998) Double-bind, controlled study of prulifloxacin in comparison with ciprofloxacin in the treatment of acute uncomplicated lower urinary tract infection. Angelini-ACRAF S.p.A., Rome (data on file) Zagni R, Orticelli G, Rosignoli MT, Dionisio P (1998) Double-bind, controlled study of prulifloxacin in comparison with ciprofloxacin in the treatment of acute uncomplicated lower urinary tract infection. Angelini-ACRAF S.p.A., Rome (data on file)
23.
Zurück zum Zitat Picollo R, Brion N, Gualano V, Millérioux L, Marchetti M, Rosignoli MT, Dionisio P (2003) Pharmacokinetics and tolerability of prulifloxacin after single oral administration. Arzneimittelforschung 53:201–205PubMed Picollo R, Brion N, Gualano V, Millérioux L, Marchetti M, Rosignoli MT, Dionisio P (2003) Pharmacokinetics and tolerability of prulifloxacin after single oral administration. Arzneimittelforschung 53:201–205PubMed
25.
Zurück zum Zitat Roveta S, Schito AM, Marchese A, Schito GC (2005) Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa. Int J Antimicrob Agents 26:366–372PubMedCrossRef Roveta S, Schito AM, Marchese A, Schito GC (2005) Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa. Int J Antimicrob Agents 26:366–372PubMedCrossRef
Metadaten
Titel
Prophylactic single-dose prulifloxacin for catheter-associated urinary tract infection after tension-free vaginal tape procedure
verfasst von
Fabio Ghezzi
Maurizio Serati
Antonella Cromi
Stefano Uccella
Stefano Salvatore
Pierfrancesco Bolis
Publikationsdatum
01.07.2007
Verlag
Springer-Verlag
Erschienen in
International Urogynecology Journal / Ausgabe 7/2007
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-006-0233-4

Weitere Artikel der Ausgabe 7/2007

International Urogynecology Journal 7/2007 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.